Exclusive Summary

• First-in-class dual-mechanism profile: Combines GABA(A)R positive allosteric modulation with NET/DAT inhibition for the treatment of Major Depressive Disorder (MDD) and Epilepsy.
• Potential for rapid onset of action: Preclinical data shows significant antidepressant effects within 24 hours to 3 days, directly addressing the 2-4 week delay typical of standard therapies.
• Superior safety margin over competitors: Demonstrates a 5-fold wider therapeutic window compared to the approved drug Zurzuvae (SAGE-217), with a built-in NET/DAT wakefulness mechanism that significantly mitigates sedation and somnolence.
• Favorable formulation and clinical status: Developed as an oral tablet ensuring high patient compliance, supported by ongoing Phase I data showing linear pharmacokinetics and no severe adverse events (SAEs).
• Strong foundation for global commercialization: PCT patents have already entered major pharmaceutical markets including the US, EU, and Japan, making it a highly attractive, de-risked asset for big pharma licensing.

Asset Materials

Contact Us for Full Materials